Latest News and Press Releases

ALK announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for EURneffy® 1 mg, the first and only needle-free adrenaline treatment for...

ZURICH, June 12, 2026 (GLOBE NEWSWIRE) -- As allergic diseases continue to affect hundreds of millions of people worldwide and place growing pressure on healthcare systems, the European Academy of...

Over half (54%) of adults at risk of anaphylaxis admit they have been without their adrenaline auto-injector (AAI) when needed—and nearly 40% do not carry one regularly (n=1,238 ).1HCP survey data...

At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which will this year take part in Istanbul, Türkiye from 12 to 15 June 2026, the Danish pharmaceutical company...

EAACI, together with AEPNAA, SEAIC, and SEICAP, has called for urgent action to improve the safety of children at risk of anaphylaxis in schools.

Today, ALK announced that children aged 4 and older living with severe allergies across the EU can now access the first and only needle-free adrenaline treatment for anaphylaxis, after the European...

ALK presents new findings that directly compare user preference between needle-free nasal and injectable adrenaline treatments for anaphylaxis.

TEMECULA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- ODRescue™, a program of FFF Enterprises, Inc. — the nation’s most trusted specialty drug distributor and diversified healthcare company — today...

Washington, DC, Aug. 27, 2025 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) announces the availability of the first validated food allergy anaphylaxis action plan,...

Life-threatening allergies may be triggered by respiratory virus vaccines, such as influenza and COVID. Repeated doses may sensitize patients.